News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in Medicine
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Latest Executive Roundtables|
Asembia 2025 |
Sales Effectiveness
Advertisement
|Articles|June 7, 2016

Transforming Commercial Models

Author(s)Sponsor's Content
Advertisement

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Advertisement

Related Content

Advertisement
Pharmaceutical Executive

Pharmaceutical Executive Daily: Susan G. Komen Releases Breast Cancer Outlook for 2026

ByNicholas Jacobus
February 4th 2026
Stock.adobe.com

Novo Nordisk Releases 2025 Financial Report and 2026 Sales and Operations Profit Outlook

ByNicholas Jacobus
February 4th 2026
Stock.adobe.com

Novartis’ Q4 Recap Shows Signs of Looming Patent Cliff

ByNicholas Jacobus
February 4th 2026
Stock.adobe.com

Susan G. Komen Releases Breast Cancer Progress Outlook for 2026

ByNicholas Jacobus
February 4th 2026
Stock.adobe.com

Pharmaceutical Executive Daily: SanegeneBio's $1.5 Billion License Agreement with Genentech

ByNicholas Jacobus
February 3rd 2026
Advertisement
Advertisement

Trending on PharmExec

1

Novo Nordisk Releases 2025 Financial Report and 2026 Sales and Operations Profit Outlook

2

Novartis’ Q4 Recap Shows Signs of Looming Patent Cliff

3

Eli Lilly Announces New $3.5 Billion Manufacturing Facility in Pennsylvania

4

FDA Rejects AstraZeneca’s Application for Subcutaneous Indication of Saphnelo

5

From OR to Office: How Workflow Change and AI Are Reshaping MedTech Adoption

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us